Intrathecal therapy: What has changed with the introduction of ziconotide

Pain Practice

Volumn 9, Issue 5, 2009, Pages 338-347

  Kress, Hans G ^a   Simpson, Karen H ^b   Marchettini, Paolo ^c,d   Ver Donck, Ann ^e   Varrassi, Giustino ^f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d Professional University School   (Switzerland)

^e General Hospital St Jan   (Belgium)

^f UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Intrathecal; Opioids; Pain; Polyanalgesic consensus; Ziconotide

Indexed keywords

BUPIVACAINE; CLONIDINE; FENTANYL; HYDROMORPHONE; MORPHINE; OMEGA CONOTOXIN MVIIA;

ANALGESIA; CHRONIC PAIN; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; PAIN ASSESSMENT; REVIEW;

ANALGESICS, NON-NARCOTIC; HUMANS; INJECTIONS, SPINAL; OMEGA-CONOTOXINS; PAIN;

EID: 77952237542     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2009.00308.x     Document Type: Review

References (42)

1. Coombs DW, Fine N. Spinal anesthesia using subcutaneously implanted pumps for intrathecal drug infusion. Anesth Analg. 1991, 73:226-231.
2. Bennett G, Burchiel K, Buchser E, Classen A, Deer T, Du Pen S. Clinical guidelines for intraspinal infusion: report of an expert panel. PolyAnalgesic Consensus Conference 2000. J Pain Symptom Manage 2000, 20:S37-S43.
3. Hassenbusch SJ, Portenoy RK. Current practices in intraspinal therapy-a survey of clinical trends and decision making. J Pain Symptom Manage 2000, 20:S4-11.
4. Hassenbusch SJ, Portenoy RK, Cousins M, Buchser E, Deer TR, Du Pen SL. Polyanalgesic consensus conference 2003: an update on the management of pain by intraspinal drug delivery-report of an expert panel. J Pain Symptom Manage 2004, 27:540-563.
5. Deer T, Krames E, Hassenbusch S, Burton AW, Caraway D, Du Pen S. Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2007, 10:300-328.
6. Bennett G, Serafini M, Burchiel K, Buchser E, Classen A, Deer T. Evidence-based review of the literature on intrathecal delivery of pain medication. J Pain Symptom Manage 2000, 20:S12-S36.
7. Deleo JA. Basic science of pain. J Bone Joint Surg Am 2006, 88(2):58-62. Suppl
8. Wallace MS. Treatment options for refractory pain: the role of intrathecal therapy. Neurology 2002, 59:S18-S24.
9. Bernards CM. Mechanisms of drug distribution within and between the epidural and intrathecal spaces and their clinical relevance. American Society of Anesthesiologists. 58th Annual Refresher Course Lectures and Basic Science Reviews 2007, 208-231. 13-10-2007
10. Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 2006, 105:169-178.
11. Rigler ML, Drasner K. Distribution of catheter-injected local anesthetic in a model of the subarachnoid space. Anesthesiology 1991, 75:684-692.
12. Tejwani GA, Rattan AK. The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat. Anesth Analg. 2002, 94:1542-1546. table
13. Zhang Y, Conklin DR, Li X, Eisenach JC. Intrathecal morphine reduces allodynia after peripheral nerve injury in rats via activation of a spinal A1 adenosine receptor. Anesthesiology 2005, 102:416-420.
14. Zhao C, Tall JM, Meyer RA, Raja SN. Antiallodynic effects of systemic and intrathecal morphine in the spared nerve injury model of neuropathic pain in rats. Anesthesiology 2004, 100:905-911.
15. Coda B, Tanaka A, Jacobson RC, Donaldson G, Chapman CR. Hydromorphone analgesia after intravenous bolus administration. Pain 1997, 71:41-48.
16. Pasero C, McCaffery M. Hydromorphone. Am J Nurs 2001, 101:22-23.
17. Coffey RJ, Burchiel K. Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery 2002, 50:78-86.
18. Miele VJ, Price K, Bloomfield S, Hogg J, Bailes J. Intrathecal morphine therapy related granulomas: two case reports. W V Med J. 2006, 102:16-18.
19. Miele VJ, Price KO, Bloomfield S, Hogg J, Bailes JE. A review of intrathecal morphine therapy related granulomas. Eur J Pain. 2006, 10:251-261.
20. Allen JW, Horais KA, Tozier NA, Yaksh TL. Opiate pharmacology of intrathecal granulomas. Anesthesiology 2006, 105:590-598.
21. Allen JW, Horais KA, Tozier NA, Wegner K, Corbeil JA, Mattrey RF. Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs: a combined magnetic resonance imaging and histopathology investigation. Anesthesiology 2006, 105:581-589.
22. Horais K, Hruby V, Rossi S, Cizkova D, Meschter C, Dorr R. Effects of chronic intrathecal infusion of a partial differential opioid agonist in dogs. Toxicol Sci. 2003, 71:263-275.
23. Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician 2007, 10:357-366.
24. Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician. 2007, 10:479-491.
25. Scherens A, Kagel T, Zenz M, Maier C. Long-term respiratory depression induced by intrathecal morphine treatment for chronic neuropathic pain. Anesthesiology 2006, 105:431-433.
26. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000, 85:2215-2222.
27. Snutch TP. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx 2005, 2:662-670.
28. Skov MJ, Beck JC, de Kater AW, Shopp GM. Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class. Int J Toxicol. 2007, 26:411-421.
29. Rauck RL, Wallace MS, Leong MS, Minehart M, Webster LR, Charapata SG. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006, 31:393-406.
30. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004, 291:63-70.
31. Wallace M, Charapata S, Fisher R, Byas-Smith M, Staats P, Mayo M. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 2006, 9:75-86.
32. Ummenhofer WC, Arends RH, Shen DD, Bernards CM. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology 2000, 92:739-753.
33. Chan JH, Heilpern GN, Packham I, Trehan RK, Marsh GD, Knibb AA. A prospective randomized double-blind trial of the use of intrathecal fentanyl in patients undergoing lumbar spinal surgery. Spine 2006, 31:2529-2533.
34. Shields D, Montenegro R, Ragusa M. Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. Neuromodulation 2005, 8:257-263.
35. Wallace MS, Kosek PS, Staats P, Fisher R, Schultz DM, Leong M. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med. 2008, 9:271-281.
36. Webster LR, Fakata KL, Charapata S, Fisher R, Minehart M. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med. 2008, 9:282-290.
37. Mironer YE, Haasis JC, Chapple I, Brown C, Satterthwaite JR. Efficacy and safety of intrathecal opioid/bupivacaine mixture in chronic nonmalignant pain: a double blind, randomized, crossover, multicenter study by the National Forum of Independent Pain Clinicians (NFIPC). Neuromodulation 2009, 5:208-213.
38. Buchser E, Durrer A, Chedel D, Mustaki JP. Efficacy of intrathecal bupivacaine: how important is the flow rate? Pain Med. 2004, 5:248-252.
39. Fogarty DJ, Carabine UA, Milligan KR. Comparison of the analgesic effects of intrathecal clonidine and intrathecal morphine after spinal anaesthesia in patients undergoing total hip replacement. Br J Anaesth. 1993, 71:661-664.
40. Shields D, Montenegro R. Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation 2007, 10:6-11.
41. Shields D, Montenegro R, Aclan J. Chemical stability of an admixture combining ziconotide and bupivacaine during simulated intrathecal administration. Neuromodulation 2007, 10:1-5.
42. Nitescu P, Dahm P, Appelgren L, Curelaru I. Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of " refractory" nonmalignant pain. Clin J Pain. 1998, 14:17-28.